Inactive Instrument

BrainsWay Ltd. Stock TEL AVIV STOCK EXCHANGE

Equities

BWAY

IL0011007189

Advanced Medical Equipment & Technology

Financials

Sales 2024 * 38.89M 146M 53.42M Sales 2025 * 45.41M 171M 62.37M Capitalization 99.67M 375M 137M
Net income 2024 * - 0 0 Net income 2025 * 2M 7.52M 2.75M EV / Sales 2024 * 2.56 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 2.19 x
P/E ratio 2024 *
-
P/E ratio 2025 *
-
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 80.17%
More Fundamentals * Assessed data
Dynamic Chart
BrainsWay Ltd. Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in Canada CI
BrainsWay Ltd. Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS for Depression for the Month of June 2024 CI
Brainsway's Deep Transcranial Magnetic Stimulation Gets Expanded FDA Labeling; Shares Rise MT
BrainsWay Ltd. Receives Expanded FDA Labeling to Treat Late Life Depression CI
Oppenheimer Adjusts Brainsway Price Target to $11 From $10, Maintains Outperform Rating MT
HC Wainwright Adjusts Price Target on Brainsway to $15 From $13, Keeps Buy Rating MT
Transcript : BrainsWay Ltd., Q1 2024 Earnings Call, May 08, 2024
BrainsWay Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
BrainsWay Ltd. Reiterates Revenue Guidance for the Year 2024 CI
Brainsway Expands Deep Tms Access in Israel Following Significant Increase in Reimbursement Rates CI
BrainsWay Ltd. Announces Publish Review Results Highlighting Potential of Deep Transcranial Magnetic Stimulation (Deep TMS?) as a Novel Therapeutic Approach for Parkinson's Disease CI
Brainsway Announces Positive Results in Late-Life Depression Post-Marketing Analysis CI
BrainsWay Ltd. Broadens Partnership with Katie?s Way Plus Through Order of an Additional 18 Deep TMS? Systems CI
Transcript : BrainsWay Ltd., Q4 2023 Earnings Call, Mar 06, 2024
BrainsWay Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
More news
Managers TitleAgeSince
Chief Executive Officer 52 14-09-13
Founder 54 06-04-30
Founder 72 06-11-06
Members of the board TitleAgeSince
Director/Board Member 68 18-11-30
Director/Board Member 73 17-12-02
Chairman 52 23-01-11
More insiders
Brainsway Ltd is an Israel-based company engaged in the development and marketing of medical devices for the treatment of various neurological and psychopathological disorders. The Company primarily offers Transcranial Magnetic Stimulation (TMS) system, a medical device that enables direct non-invasive activation of deep brain structures. Its TMS system uses magnetic pulses to stimulate neurons and consequently modulates the physiological activity of the brain. TMS system is used in various clinical applications including: major depressive disorders, obsessive-compulsive disorder, smoking addiction and others various psychiatric, neurological, and addiction disorders.
More about the company